

CASE STUDY

Enabling Diversity in Cancer Screening Study.

Science 37 quickly enrolls representative patient population for real-world diagnostic study

SITUATION

Ensuring diverse patient representation

The sponsor, conducting a blood assay study for cancer screening, aimed to detect all cancers rather than investigating a specific indication, such as colorectal cancer. Science 37 offered a flexible approach to quickly access a more representative patient population.

SOLUTION

Relying on the **power of our specialized networks**

Utilizing the Science 37 Operating System, underpinned by our end-to-end technology platform and specialized networks, we were able to tap into our Global Healthcare Provider Network to identify sites that could enroll patients via high-recruiting providers.

IMPACT

Exceeding enrollment and diversity goals

Leveraging our specialized networks, versus a direct-topatient approach, we were able to achieve faster enrollment and increased diversity.



Exceeded enrollment forecast by over an eight-week period



Surpassed the study's Hispanic representation goals with 56% of study samples

"This success demonstrates how quickly we can enroll and complete this type of real-world study. It demonstrates the potential of the Science 37 Operating System to accelerate the development of important diagnostics that can help detect cancers sooner and in less invasive ways. It's a good problem to have when you deliver more than what the sponsor needs."

- Ali Dawson, Senior Clinical Study Lead

Our bespoke approach to every trial

We take a bespoke approach to all our trials. We understand every therapeutic area is different and perform careful review of trial design, inclusion/exclusion criteria and review of the specific needs and/or study participation challenges expressed from diverse patients and providers to do our part to **reduce barriers and support clinical trial equity**.

Let's Talk.

Please contact us at **diversityinnovation@science37.com** to learn more about how we do Diversity in Clinical Trials.

About Science 37

Science 37 accelerates clinical research by enabling universal access to patients and providers, anywhere. The Science 37 Operating System[™]—underpinned by an end-to-end technology platform and supported by specialized networks to enable trial orchestration—enables up to 15x faster trial enrollment, 28% greater patient retention and 3x more diversity. Science 37 and its Operating System can be configured to conduct the full clinical trial, act as a virtual site (known as Metasite[™]) or deploy its technology in combination with any of its specialized networks to enable flexibility across nearly any study design. Founded in 2014 as a pioneer in decentralized clinical trials, Science 37 has conducted more fully decentralized, interventional clinical trials than any other provider and has the most complete Operating System.



